Background: Little is known concerning the relative effectiveness of LTRAs compared to ICSs as monotherapy or LABA as add-on therapy in the Asian population.
Objectives: In this retrospective cohort study, we examined the comparative effectiveness of montelukast to ICS as a first-line monotherapy and as an add-on in comparison with LABA on asthma exacerbations among Asian and non -Hispanic white persistent asthma patients in a large managed care organization.
Methods: The three add-on comparisons were montelukast plus low-dose ICS versus LABA plus low-dose ICS, montelukast plus low-dose ICS versus medium-dose ICS, and montelukast plus medium-dose ICS versus LABA plus medium-dose ICS. Patients were identified based on ICD-9 diagnosis codes and administrative pharmacy dispensing. Exacerbations were defined as asthma emergency department visit or hospitalization, or asthma outpatient visits requiring systemic corticosteroid dispensing. Patient demographic and clinical characteristics were balanced by using inverse probability treatment weighting. Multivariable robust Poisson and Cox-proportional hazards regression models were applied to estimate rate ratios and hazard ratios.
Results: Compared with low-dose ICS monotherapy, montelukast monotherapy evidenced a lower incidence rate (RR 0.89, CI 0.79-0.99, p = 0.03) but similar hazard rate (HR 0.96, CI 0.86-1.06, p = 0.43) of asthma exacerbation in white patients 12 years of age or older. No difference was observed in Asian patients or in white children 4-11 years of age. All other comparisons did not reveal a statistically significant difference in incidence or hazard rate.
Conclusion: In a real-world comparative effectiveness study, asthma exacerbation rates were similar among guideline alternative controller regimens in Asians and whites.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12932/AP-210617-0105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GINA step 1-2 therapy: Low-dose ICSformoterol combination taken as needed or moderate-dose ICS-formoterol combination taken as needed?
Tuberk Toraks
December 2024
Division of Immunology and Allergy, Department of Chest Diseases, Erciyes University Faculty of Medicine, Kayseri, Türkiye.
As-Needed Inhaled Corticosteroid-Formoterol in a Single Inhaler Compared to Inhaled Corticosteroid-Albuterol in Separate Inhalers as Reliever Therapy in Mild Pediatric Asthma: A Cost-Utility Analysis.
Pediatr Pulmonol
December 2024
Department of Pharmacology and Toxicology, School of Medicine, Research Group in Pharmacology and Toxicology (INFARTO), Universidad de Antioquia, Medellín, Colombia.
Objectives: Since 2019 as-needed low-dose ICS-formoterol in a single inhaler has been recommended for treatment of mild asthma in children aged more than 12 years. Alternatively, the use of ICS-albuterol has been proposed in countries where ICS-formoterol is not available or affordable. The aim of the present study was to evaluate the cost-utility of as-needed ICS-albuterol in separate inhalers compared to ICS-formoterol in a single inhaler as reliever therapy in pediatric patients with mild asthma living in Colombia.
View Article and Find Full Text PDFModification of asthma treatment efficacy by healthcare access: A reanalysis of AsthmaNet Step-Up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations (STICS) clinical trial.
Respir Med
November 2024
Drexel University Dornsife School of Public Health, Department of Environmental and Occupational Health, USA.
Background: While randomized controlled trials (RCTs) in asthma management are designed to balance known and unknown variables across treatment groups, including social and environmental co-exposures, it remains important to consider how these co-exposures influence disease progression and treatment outcomes. The importance of considering socio-environmental co-exposures in the context of asthma is twofold: 1) asthma disproportionately affects low-income urban communities, where air pollution and chronic stress are pervasive; and 2) despite the wide range of asthma treatments, inadequate disease control persists.
Methods: In the present ancillary study of the Step-Up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations (STICS) RCT, we investigated how socio-environmental factors, such as air pollution exposure and healthcare access, modify the effect of inhaled corticosteroid (ICS) therapy in children with asthma.
Adverse Impacts of Corticosteroid Treatment on Osteoporosis/Osteopenia in Adult Asthmatics: A Retrospective ICARUS Cohort Study.
J Allergy Clin Immunol Pract
October 2024
Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea. Electronic address:
Article Synopsis
- The study investigates the long-term effects of inhaled corticosteroids (ICS) and oral corticosteroids (OCS) on bone health in adults with asthma, specifically looking at osteoporosis, osteopenia, and fractures.
- Data was collected from electronic health records of patients at Ajou University Medical Center in Korea, with a focus on outcomes over 5 years for those on maintenance therapy involving ICS and/or OCS.
- Findings indicate that high-dose OCS is linked to a significantly higher risk of osteoporosis and fractures, especially in women over 50, while high-dose ICS is associated with an increased risk of osteopenia.
Article Synopsis
- The study investigates the prevalence of oral candidiasis (OC) among patients with asthma and COPD undergoing inhaled corticosteroid (ICS) therapy at the Philippine General Hospital from October 2019 to January 2020.
- Results showed that 5.97% of ICS users had OC, with a prevalence range of 1.65% to 14.59%, but the small sample size limited definitive conclusions.
- The findings indicate some associations, like higher OC prevalence in adult females on low dose Fluticasone/Salmeterol DPI for over a year, and suggest that larger studies are needed to explore the relationship between OC and ICS therapy factors more thoroughly.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!